Content area
Full Text
The points below highlight changes in marketing authorisations that may have a significant impact on veterinary surgeons' prescribing decisions. The VMD would like to emphasise the importance of reviewing prescribing practices and decisions made under the prescribing cascade in the light of new or updated authorisations. Prescribing decisions need to be based on individual clinical circumstances and, although the use of newly authorised medicines may not always be appropriate, especially where a patient is already stabilised on medication for a chronic disease, for new clinical cases the authorised product should be used as a first choice unless there is a clear clinical imperative that suggests otherwise.
New marketing authorisations
The following new marketing authorisations have been approved since February 28, 2010. Entries in blue bold type indicate products containing active substances not previously included in authorised veterinary medicinal products in the UK: Animex 0.8 mg/ml oral solution for sheep.
BadgerBCG (live bacterial vaccine for the active immunisation of badgers to reduce the lesions of tuberculosis caused by Mycobacterium bovis ).
E mpraSan Extracare 0.6% w/v ready-touse teat dip/teat spray solution.
E nroxil Max 100 mg/ml solution for injection for cattle.
E nurace 10, 10 mg tablets for dogs.
Fenflor 300 mg/ml solution for injection for cattle, florfenicol.
Fenflor 300 mg/ml solution for injection for pigs, florfenicol.
Fenoflox 100 mg/ml solution for use in drinking water for chickens and turkeys.
Ketodale 100 mg/ml solution for injection for horses, cattle and swine.
Loxicom 0.5 mg/ml suspension for cats.
Maxxene Spot On Cat 10% w/v spot on solution.
Phenoleptil 12.5 mg tablets for dogs.
Phenoleptil 50 mg tablets for dogs.
Prascend 1 mg tablets for horses (pergolide as pergolide mesylate, for the treatment of clinical signs associated with pituitary pars intermedia dysfunction, PPID [equine Cushing's disease]).
Rexxan Spot On Cat 10% w/v spot on solution.